AG
GTHX

Algert Global’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Algert Global’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-38,470
Closed -$117K – 1316
2023
Q4 		$117K Sell
38,470
-29,630
-44% -$55.7K ﹤0.01% 1059
2023
Q3 		$98K Buy
+68,100
New +$132K ﹤0.01% 1033
2021
Q1 		– Sell
-18,750
Closed -$337K – 553
2020
Q4 		$337K Buy
18,750
+7,540
+67% +$113K 0.1% 286
2020
Q3 		$129K Sell
11,210
-4,392
-28% -$72.5K 0.04% 345
2020
Q2 		$379K Buy
15,602
+2,721
+21% +$45K 0.13% 236
2020
Q1 		$142K Buy
+12,881
New +$241K 0.06% 332

Other funds holding GTHX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Algert Global's GTHX Position: Q1 2024 in Review

Algert Global sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q1 2024, closing a stake of 38,470 shares — an estimated $117K sold.

Algert Global first reported a position in GTHX in Q1 2020 and held it in 6 quarters. The position peaked at $379K in Q2 2020. 86 funds tracked by Wall St. Rank hold GTHX as of Q1 2024.

  • Algert Global reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Algert Global sold 38,470 G1 Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $117K.
  • Algert Global first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2020 and held it in 6 quarters.
  • Algert Global's G1 Therapeutics, Inc. Common Stock position peaked at $379K in Q2 2020.
  • 86 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Algert Global's 13F filing for Q1 2024, filed 15 May 2024.